Floatz logo

16 assets in Bipolar II Disorder

Therapeutic assets addressing Bipolar II Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone
Bipolar II Disorder
Joshua RosenblatP4BB (68)
Dexmedetomidine
Bipolar II Disorder
BioXcel Therapeutics IncP3BB (68)
Quetiapine
Bipolar II Disorder
First Affiliated Hospital of Zhejiang UniversityP4BB (68)
Lamotrigine
Bipolar II Disorder
University Hospital Bispebjerg and FrederiksbergP4BB (67)
Lithium, Elemental
Bipolar II Disorder
University Hospital Bispebjerg and FrederiksbergP4BB (66)
Naltrexone
Bipolar II Disorder
Mayo ClinicP4B (62)
Semaglutide
Bipolar II Disorder
Mayo ClinicP4B (62)
Teonanacatl
Bipolar II Disorder
Lakshmi N YathamP3B (62)
Midazolam
Bipolar II Disorder
Joshua RosenblatP2B (61)
Abbv-932
Bipolar II Disorder
AbbVieP2B (57)
Acetylcysteine
Bipolar II Disorder
Medical University of South CarolinaP2B (57)
Encukalner
Bipolar II Disorder
Xenon Pharmaceuticals Inc.P3B (57)
Gabapentin
Bipolar II Disorder
Medical University of South CarolinaP2B (57)
Navacaprant
Bipolar II Disorder
Neumora Therapeutics, Inc.P2B (57)
gh001
Bipolar II Disorder
GH Research Ireland LimitedP2CCC (53)
Icalcaprant
Bipolar II Disorder
AbbVieP2CCC (53)